Sort   by:  
 Page size 
ProteomicsEvolutionarily-conserved FOXO-regulated OSER1 extends lifespan and healthspan
Molecular aging reflects the time-dependent accumulation of cellular damage and loss of essential cellular functions. FOXO transcription factors and their downstream targets play critical roles in the response to aging-associated cellular damage. Here, we identify and characterize a novel FOXO-regul...
ORGANISM(S): Homo sapiens (Human) 
2024-07-25 | PXD036579 | Pride
Oser1 Lifespan 
UnknownFOXO-regulated OSER1 reduces oxidative stress and extends lifespan in multiple species.
Not available
S-EPMC11336091 | biostudies-literature
UnknownSingle-nucleotide polymorphism rs4142441 and MYC co-modulated long non-coding RNA OSER1-AS1 suppresses non-small cell lung cancer by sequestering ELAVL1.
Not available
S-EPMC8177763 | biostudies-literature
UnknownOptimization of rice panicle architecture by specifically suppressing ligand-receptor pairs.
Not available
S-EPMC10039049 | biostudies-literature
UnknownPhylogenetic and CRISPR/Cas9 Studies in Deciphering the Evolutionary Trajectory and Phenotypic Impacts of Rice ERECTA Genes.
Not available
S-EPMC5902711 | biostudies-literature
UnknownTranscriptome analysis combined with Mendelian randomization screening for biomarkers causally associated with diabetic retinopathy.
Not available
S-EPMC11251905 | biostudies-literature
OtherGenome-wide CRISPR-Cas9 knockout screening identifies NUDCD2 depletion as sensitizer for bortezomib, carfilzomib and ixazomib in multiple myeloma [CRISPR screen bortezomib]
Background/Objectives: The treatment of multiple myeloma (MM) remains a challenge as almost all patients will eventually relapse. Proteasome inhibitors are a cornerstone in the management of MM. Unfortunately, validated biomarkers predict-ing drug response are largely missing. Therefore, we aimed to...
ORGANISM(S): Homo sapiens 
2025-07-16 | GSE301947 | GEO
TranscriptomicsGenome-wide CRISPR-Cas9 knockout screening identifies NUDCD2 depletion as sensitizer for bortezomib, carfilzomib and ixazomib in multiple myeloma.
Background/Objectives: The treatment of multiple myeloma (MM) remains a challenge as almost all patients will eventually relapse. Proteasome inhibitors are a cornerstone in the management of MM. Unfortunately, validated biomarkers predict-ing drug response are largely missing. Therefore, we aimed to...
ORGANISM(S): Homo sapiens 
2025-07-16 | GSE301632 | GEO
OtherGenome-wide CRISPR-Cas9 knockout screening identifies NUDCD2 depletion as sensitizer for bortezomib, carfilzomib and ixazomib in multiple myeloma [CRISPR screen carfilzomib]
Background/Objectives: The treatment of multiple myeloma (MM) remains a challenge as almost all patients will eventually relapse. Proteasome inhibitors are a cornerstone in the management of MM. Unfortunately, validated biomarkers predict-ing drug response are largely missing. Therefore, we aimed to...
ORGANISM(S): Homo sapiens 
2025-07-16 | GSE301948 | GEO
UnknownTrans-ancestry, Bayesian meta-analysis discovers 20 novel risk loci for inflammatory bowel disease in an African American, East Asian and European cohort.
Not available
S-EPMC9941836 | biostudies-literature
Sort   by:  
 Page size